Deciphera Pharmaceuticals CEO Steven Hoerter's 2021 pay jumps 21% to $9.4M
Deciphera Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: April 26, 2022
Deciphera Pharmaceuticals reported fiscal year 2021 executive compensation information on April 26, 2022.
In 2021, five executives at Deciphera Pharmaceuticals received on average a compensation package of $4.5M, a 31% increase compared to previous year.
Average pay of disclosed executives at Deciphera Pharmaceuticals
Steven L. Hoerter, Chief Executive Officer, received $9.4M in total, which increased by 21% compared to 2020. 89% of Hoerter's compensation, or $8.4M, was in option awards. Hoerter also received $324K in non-equity incentive plan, $676K in salary, as well as $12K in other compensation.
For fiscal year 2021, the median employee pay was $290,520 at Deciphera Pharmaceuticals. Therefore, the ratio of Steven L. Hoerter's pay to the median employee pay was 32 to one.
Matthew L. Sherman, Chief Medical Officer, received a compensation package of $3.5M, which increased by 166% compared to previous year. 61% of the compensation package, or $2.1M, was in option awards.
Daniel L. Flynn, Chief Scientific Officer, earned $3.4M in 2021, a 27% increase compared to previous year.
Thomas P. Kelly, Chief Financial Officer, received $3.4M in 2021, which increases by 27% compared to 2020.
Daniel C. Martin, Chief Commercial Officer, earned $2.7M in 2021, a 1% increase compared to previous year.
Related executives
Steven Hoerter
Deciphera Pharmaceuticals
Chief Executive Officer
Thomas Kelly
Deciphera Pharmaceuticals
Chief Financial Officer
Matthew Sherman
Deciphera Pharmaceuticals
Chief Medical Officer
Daniel Flynn
Deciphera Pharmaceuticals
Chief Scientific Officer
Daniel Martin
Deciphera Pharmaceuticals
Chief Commercial Officer
You may also like
Source: SEC filing on April 26, 2022.